Clinical Trials Browser

Not yet recruiting × Neoplasm, Residual × osimertinib × Clear all

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3 Not yet recruiting

Lung Neoplasms, Neoplasm, Residual